Companies and scientists in the West are keen to test their drugs in China, which is an important future market. But those running clinical trials need to be on their guard, says David Cyranoski.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
http://www.nature.com/uidfinder/10.1038/nbt1204-1497
http://www.nature.com/uidfinder/10.1038/nm1204-1283
http://www.nature.com/uidfinder/10.1038/419334a
Related external links
Chinese State Food and Drug Administration
US National Institutes of Health bioethics resources — Human Subjects Research and IRBs
Rights and permissions
About this article
Cite this article
Cyranoski, D. Consenting adults? Not necessarily.... Nature 435, 138 (2005). https://doi.org/10.1038/435138a
Published:
Issue date:
DOI: https://doi.org/10.1038/435138a
This article is cited by
-
Production: Vaccines from the East
Nature (2014)
-
Experimental Labour—Offshoring Clinical Trials to China
East Asian Science, Technology and Society: an International Journal (2008)
-
Bioethics in China
EMBO reports (2006)
-
Correction
Nature (2005)
-
Japan-China merger puts growth in East Asia first
Nature Biotechnology (2005)
